Skip to main content

Anti-Rheumatic Rx

      RT @drdavidliew: The key data for treating clinically suspect arthralgias (CSA):
      TREAT-EARLIER (MTX)
      ARIAA, APIPPRA (aba
      1 year 6 months ago
      The key data for treating clinically suspect arthralgias (CSA): TREAT-EARLIER (MTX) ARIAA, APIPPRA (abatacept) but what we need to do going forward: stratify pts better for studies predict individual risk better, to weight up risk-benefit of intervention #EULAR2023 @RheumNow https://t.co/h3gNIyLxPY
      Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https:/
      1 year 6 months ago
      Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
      RT @synovialjoints: Study on folylPG synthétase (FPGS) activity and MTX-PG measured in sperm showed low bio active form
      1 year 6 months ago
      Study on folylPG synthétase (FPGS) activity and MTX-PG measured in sperm showed low bio active form of MTX-PG, low FPGS activity resulting in lower capacity to form MTX-PG, Perez-Garcia LF, Abst#OP0224 #EULAR2023 @RheumNow https://t.co/8sGQOBxn8r
      RT @synovialjoints: Herpes Zoster vaccination in RA patients treated with Upadacitinib and MTX showed a satisfactory res
      1 year 6 months ago
      Herpes Zoster vaccination in RA patients treated with Upadacitinib and MTX showed a satisfactory response, slight reduction in response compared to general population in both antibody and cell mediated responses Winthrop K, Abst#OP0225 #EULAR2023 @RheumNow https://t.co/wxwbOYsn5K
      RT @Janetbirdope: To treat or not? Clinically suspect arthralgia does affect QoL including function. Both premises of tr
      1 year 6 months ago
      To treat or not? Clinically suspect arthralgia does affect QoL including function. Both premises of treating with a DMARD are valid. OverRx v missing the very early window of opportunity @RheumNow #EULAR2023 @eular_org https://t.co/86CVZ2IjEf
      RT @drdavidliew: For our rheum patients who have had cancer previously - the default can’t be to not have DMARDs.

      @eu
      1 year 6 months ago
      For our rheum patients who have had cancer previously - the default can’t be to not have DMARDs. @eular_org points to consider SLR: no clear risk, across b/tsDMARDs For too long these patients were unnecessarily asked to ride it out. No more please POS1069 #EULAR2023 @RheumNow https://t.co/7m4Yh0h7rd
      RT @Janetbirdope: Should immunosuppression be used to improve #PAH in #SSc added to PAH Rx (85%) Morbidity or mortality
      1 year 6 months ago
      Should immunosuppression be used to improve #PAH in #SSc added to PAH Rx (85%) Morbidity or mortality outcomes >700 pts - half had a DMARD after dx RheumNow #EULAR2023 OP0238 Targeted Rx improved esp RTX\TCZ findings V interesting results #GameChanger May change my Rx practice!
      RT @AurelieRheumo: Retro French database study shows reassuring data.

      Overall mortality after IRAEs =similar between p
      1 year 6 months ago
      Retro French database study shows reassuring data. Overall mortality after IRAEs =similar between pts receiving b/tsDMARDs vs. those who don't 70000+ pts treated w/ ICI, 7800+ IRAEs (most frequent colitis) & 330 treated w/ b/tsDMARDs, 10% Rheum IRAE OP0270 @RheumNow #EULAR23 https://t.co/OFNaIU4kzt
      ×